Novartis AG ADR (NVS)vsSensus Healthcare Inc (SRTS)
NVS
Novartis AG ADR
$150.38
+0.16%
HEALTHCARE · Cap: $267.60B
SRTS
Sensus Healthcare Inc
$2.77
0.00%
HEALTHCARE · Cap: $49.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 323730% more annual revenue ($56.69B vs $17.51M). NVS leads profitability with a 22.5% profit margin vs -88.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SRTS
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-56.8%
Fair Value
$93.67
Current Price
$150.38
$56.71 premium
Margin of Safety
-70.6%
Fair Value
$2.79
Current Price
$2.77
$0.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Earnings expanding 433.3% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Revenue declined 68.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SRTS
The strongest argument for SRTS centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SRTS
The primary concerns for SRTS are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while SRTS is a turnaround play — different risk/reward profiles.
SRTS carries more volatility with a beta of 1.14 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sensus Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?